ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 31 of 179 for:    sirolimus cancer | Recruiting, Not yet recruiting, Available Studies

Dose EScalation Induction of EvERolimus (Desiree)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02387099
Recruitment Status : Recruiting
First Posted : March 12, 2015
Last Update Posted : June 27, 2017
Sponsor:
Collaborator:
Novartis
Information provided by (Responsible Party):
German Breast Group

Brief Summary:

The BOLERO-2 study demonstrated a benefit for patients who received everolimus in addition to exemestane in patients who progressed during/after a non-steroidal aromatase inhibitor;

Routine use of everolimus shows an high rate of intolerability due to mucositis/stomatitis especially during the first 12 weeks of treatment leading cause for treatment discontinuation not related to tumor progression;

GeparQuinto study (setting III: non-responders): everolimus was given as salvage treatment in combination with paclitaxel for patients without response to 4 cycles epirubicin/cyclophosphamide with/without bevacizumab.

A dose-escalation schema was successfully used to improve tolerability of everolimus together with the cytotoxic Agent.

Everolimus plus exemestane has improved the prognosis of metastatic breast cancer significantly. Desiree-study aims to improve the tolerability, which is necessary in order to achieve an adequate dose intensity for the patients in Routine care.


Condition or disease Intervention/treatment Phase
Breast Cancer Hormone Receptor Positive Tumor Drug: 3 weeks Dose Induction of Everolimus Drug: 3 weeks Conventional Everolimus Dosing Drug: Open Label Phase with conventional 10mg Everolimus Dosing week 4-24 Drug: Standard Care after 24 weeks Phase 2

Detailed Description:

The BOLERO-2 study demonstrated an enormous benefit for patients who received everolimus in addition to exemestane in patients who progressed during/after a non steroidal (NSAI), which led to approval of everolimus in this indication. However, experience from routine use report a high rate of intolerability of this innovative treatment approach especially during the first 12 weeks of treatment. Most common side effect is mucositis/Mucositis which is considered the leading cause for treatment discontinuation not related to tumor progression.

This outside clinical trial experience is contrary to findings from BOLERO-2, where the number of patients still taking full-dose (10mg) of everolimus at 4, 8, and 12 weeks is 77.8%, 75.6%, and 75.6%, respectively. These findings are in concordance with non-interventional studies. However, findings might be biased by positive pre-selection.

In the non-responder part (setting III) of the neoadjuvant GeparQuinto study, everolimus was given as salvage treatment in combination with paclitaxel for patients without response to 4 cycles epirubicin/cyclophosphamide +/- bevacizumab. A dose-escalation schema was successfully used to improve tolerability of everolimus together with the cytotoxic agent. In fact the addition of everolimus to paclitaxel led only to increases of grades 1-4 leukopenia, grades 1-2 thrombocytopenia, leukopenia, skin changes and hyperlipidemia. Grades 3-4 hematological and nonhematological toxic effects were infrequent with no differences between treatment arms.

Moreover, Ravaud et al performed a metaanalysis of clinical trials in order to evaluate the potential relationship between everolimus exposure, safety and efficacy. Previous studies have shown that maximum everolimus concentrations are reached 1-2 hours after administering 5-70 mg oral doses, maximum everolimus concentrations increase in a dose-proportional manner between 5 mg and 10 mg and that continuous 5-10 mg once-daily dosing enables steady state to be achieved within 1 week.

The metaanalysis shows that a two-fold increase in the minimum concentration of everolimus increased the probability of tumor size reduction (odds ratio 1.4), which was associated with a trend for reduced risk of PFS events (risk ratio [RR] 0.9), but with an increased risk of grade 3 pulmonary toxicity (RR1.93), Mucositis (RR 1.49), and metabolic toxicity (RR 1.3).

Taking together these results suggest a dose-dependent antitumor effect of everolimus that have to be balanced against the correlated increased toxicities. For this reason the optimal dose and schedule need to be explored within randomized prospective clinical trial, in order to increase compliance and tolerability, maximizing efficacy.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 156 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-blind, Phase II Study to Evaluate the Tolerability of an Induction Dose Escalation of Everolimus in Patients With Metastatic Breast Cancer
Study Start Date : May 2015
Estimated Primary Completion Date : March 2018
Estimated Study Completion Date : March 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Active Comparator: Conventional Everolimus dosing according to label

everolimus 10 mg/day, week 1-3: 4x2.5 mg/day (blinded); week 4-24: 10mg/day (open according to label)

+ further treatment according to standard of care

Drug: 3 weeks Conventional Everolimus Dosing

Comparing a conventional dosing approach starting with 10 mg at first dose versus a dose-escalating schema over 21 days in patients receiving everolimus in combination with exemestane for treatment of metastatic breast cancer.

All patients will be treated within the approved indication of everolimus in combination with exemestane.

Patients will be randomized in a 1:1 ratio


Drug: Open Label Phase with conventional 10mg Everolimus Dosing week 4-24
All patients will receive open label Everolimus with Exemestane for 21 weeks according to label

Drug: Standard Care after 24 weeks
It is up to the discretion of the investigator to continue with Everolimus+Exemestane beyond 24 weeks

Experimental: 3 week Dose Induction of Everolimus

an escalating dose of everolimus as follows: week 1: 1x2.5 mg verum + 3x placebo/day; week 2: 2x2.5 mg verum + 2x placebo/day; week 3: 3x2,5 mg verum + 1x placebo/day; week 4-24: 10 mg/day (open according to label)

+ further treatment according to standard of care

Drug: 3 weeks Dose Induction of Everolimus

Comparing a conventional dosing approach starting with 10 mg at first dose versus a dose-escalating schema over 21 days in patients receiving everolimus in combination with exemestane for treatment of metastatic breast cancer.

All patients will be treated within the approved indication of everolimus in combination with exemestane.

Patients will be randomized in a 1:1 ratio


Drug: Open Label Phase with conventional 10mg Everolimus Dosing week 4-24
All patients will receive open label Everolimus with Exemestane for 21 weeks according to label

Drug: Standard Care after 24 weeks
It is up to the discretion of the investigator to continue with Everolimus+Exemestane beyond 24 weeks




Primary Outcome Measures :
  1. cumulative rate Mucositis grade 2-4 (WHO's oral toxicity scale (OTS)) [ Time Frame: week1 to week 12 ]

    To compare the cumulative rate of mucositis/stomatitis grade 2-4 (WHO's oral toxicity scale (OTS)) at 12 weeks after start of treatment using a conventional and a dose-escalating schema of everolimus in combination with exemestane in patients with metastatic breast cancer and progression or relapse after non-steroidal aromatase-inhibitor treatment.

    Endpoint measurement: First episode of mucositis WHO's OTS 2-4 any time during a 12 week period after start of everolimus



Secondary Outcome Measures :
  1. cumulative rate Mucositis grade 2-4 (WHO's oral toxicity scale (OTS)) [ Time Frame: week 1 to 24 ]

    To compare the cumulative rate of mucositis/stomatitis grade 2-4 (WHO's oral toxicity scale (OTS)) at 24 weeks after start of treatment.

    Incidence of first episodes of mucositis/stomatitis WHO's OTS grade 2-4 any time during a 24 week period.


  2. cumulative rate Mucositis any grade (WHO's oral toxicity scale (OTS)) [ Time Frame: week 1 to 12 and week 1 to 24 ]

    To compare the cumulative rate of mucositis/stomatitis grade 1 and any grade (WHO's oral toxicity scale (OTS)) at 12 and 24 weeks after start of treatment.

    Incidence of first episodes of mucositis/stomatitis WHO's OTS grade 1 and any grade any time during a 12 and 24 week period.


  3. Patients on conventional dose Everolimus 10mg [ Time Frame: week 12 and week 24 ]
    To compare the rate of patients on 10mg daily at 12 weeks and 24 weeks after start of everolimus treatment. Average dose of treatment during week 12 and during week 24.

  4. Clinical Benefit Rate (CBR) [ Time Frame: week 24 ]
    To compare the clinical benefit rate (CR, PR und SD >=16 Weeks) at 24 weeks after start of everolimus treatment. Clinical benefit rate (CBR) is defined as all patients with no evidence for tumor progression at 24 weeks after start of everolimus treatment.

  5. Safety other than Mucositis [ Time Frame: week 1 to 24 ]
    To compare the safety with regard to other organ signs and symptoms.Safety by toxicity grades in general is defined by the NCI-CTCAE version 4.03.

  6. Time to Mucositis grade 2-4 (WHO's oral toxicity scale (OTS)) [ Time Frame: week 1 to 24 ]
    To compare the time to grade ≥2 mucositis/stomatitis

  7. Cumulative Dose [ Time Frame: week 4 ]
    To compare the cumulative dose at 4 weeks

  8. RDI [ Time Frame: week 1 to 24 ]
    To compare the relative dose intensity for everolimus. Relative dose intensity for everolimus is the ratio of Actual Total Dose Intensity (ATDI) and Planned Total Dose Intensity (PTDI), expressed as a percentage.

  9. QoL FACTB [ Time Frame: week 4, week 12, End of Therapy Visit (week 25-28) ]
    To compare quality of life using the FACT-B questionnaire and the QSDQ

  10. QoL QSDQ [ Time Frame: daily till week12 ]
    To compare quality of life using the FACT-B questionnaire and the QSDQ


Other Outcome Measures:
  1. Biomarker for Breast Cancer [ Time Frame: Baseline and End of Therapy Visit (week 25-28) ]

    Other objectives:

    Potential biomarkers predicting safety and compliance will be determined after completion of study treatment




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Eligibiltiy according to Everolimus label (ie. postmenopausal women)

Inclusion Criteria (most important)

  • Locally advanced or metastatic stage of disease not amenable to curative treatment by surgery or radiotherapy alone.
  • No indication for chemotherapy (e.g. symptomatic visceral metastasis) -Histological confirmed hormone receptor-positive (HR+), HER2- negative carcinoma of the breast.
  • Postmenopausal women
  • Disease progression following prior therapy with non steroidal aromatase inhibitors (NSAI), defined as:

    1. Recurrence while on, or following completion of an adjuvant treatment with Letrozole or Anastrozole, or
    2. Progression while on or following completion of Letrozole or Anastrozole treatment for ABC/MBC. Note: Non-steroidal aromatase inhibitors (i.e. Letrozole or Anastrozole) do not have to be the last treatment prior to enrollment. Other prior anticancer therapy, e.g. Tamoxifen, Fulvestrant, Exemestane, is also allowed. Patients must have recovered to grade 1 or better from any adverse events (except alopecia) related to previous therapy prior to enrollment.
  • At least 4 weeks since radiotherapy, with full recovery. The measurable disease must be completely outside the radiation field or there must be pathologic proof of newly progressive disease.

Exclusion Criteria (most important):

  • Concurrent immunotherapy or hormonal therapy (contraceptive and/or replacement therapy). Bisphosphonates or denosumab may be continued or started before randomization.
  • Life expectancy of less than 3 months.
  • Parenchymal brain metastases, unless adequately controlled by surgery and/or radiotherapy.
  • Any ongoing toxicity from prior anti-cancer therapy that is grade 3-4 and/or that is progressing in severity, except alopecia or anemia controlled by growth factors.
  • Known or suspected congestive heart failure (>NYHA I) and/or coronary heart disease, angina pectoris requiring anti-anginal medication, previous history of myocardial infarction ≤ 6months, evidence of transmural infarction on ECG, un- or poorly controlled arterial hypertension (i.e. BP >150/100 mmHg under treatment with two antihypertensive drugs), rhythm abnormalities requiring permanent treatment, clinically significant valvular heart disease.
  • Currently active infection.
  • History of other malignancies within the last 5 years which significantly affect the diagnosis, assessment or prognosis of metastatic breast cancer.
  • Malabsorption syndrome or insufficient gastrointestinal function, preexisting diagnosis of ulcerative colitis.
  • Concurrent treatment with other experimental drugs; participation in another clinical trial with any investigational not marketed drug within 30 days prior to study entry.
  • Insufficiently controlled diabetes, known HIV infection or chronic hepatitis B or C and seriously impaired liver function (Child-Pugh, class A, B or C).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02387099


Contacts
Contact: Ioannis Gkantiragas, Dr. +49 6102 7480 ext 0 desiree@germanbreastgroup.de
Contact: Gemma Bruno, Dr +49 6102 7480 ext 0 desiree@germanbreastgroup.de

Locations
Germany
Sana Klinikum Offenbach / German Breast Group Not yet recruiting
Neu Isenburg, Hessen, Germany, 63263
Contact: Sibylle Loibl, PD.MD    +49 6102 7840 ext 426    Sibylle.Loibl@GermanBreastGroup.de   
Principal Investigator: Sibylle Loibl, MD         
TU Dresden Recruiting
Dresden, Sachsen, Germany, 01307
Principal Investigator: Karin Kast, MD, Prof         
Recruiting
Bielefeld, Germany, 33604
University of Erlangen Recruiting
Erlangen, Germany, 91054
Recruiting
Essen, Germany, 45136
Not yet recruiting
Goslar, Germany, 38642
Recruiting
Hanau, Germany, 63450
Active, not recruiting
Karlsruhe, Germany, 76135
Active, not recruiting
Kiel, Germany, 24105
Active, not recruiting
Köln, Germany, 50931
Recruiting
Mainz, Germany, 55131
Active, not recruiting
München, Germany, 80638
Recruiting
Rotenburg, Germany, 27356
Recruiting
Weinheim, Germany, 69469
Sponsors and Collaborators
German Breast Group
Novartis
Investigators
Study Chair: Sibylle Loibl, Prof., MD ASCO, ESGO, ESMO, DKG, DGGG, AGO, DGS, BIG, BCIRG, St. Gallen Faculty Member, SABCS Faculty member

Responsible Party: German Breast Group
ClinicalTrials.gov Identifier: NCT02387099     History of Changes
Other Study ID Numbers: GBG 86
First Posted: March 12, 2015    Key Record Dates
Last Update Posted: June 27, 2017
Last Verified: June 2017

Keywords provided by German Breast Group:
Stage IIIB
Stage IV
Recurrent
Metastatic

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Everolimus
Sirolimus
Breast Diseases
Skin Diseases
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents